OXURION: Oxurion signs a letter of intent for the acquisition of an international CRO

Leuven, Belgium — March 19, 2026 — Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces it has signed a letter of intent (LOI) to acquire a majority stake in an international contract research organization (CRO) with operations across Europe, North Africa, and the Middle East. The contemplated transaction is fully aligned with Oxurion’s strategy to reinforce its integrated model dedicated to clinical development.

An international CRO with a multi-country operational platform

The target company is an independent, recognized player known for the quality and breadth of its clinical operations. It supports the full clinical trial lifecycle—from Phase I to IV—covering study management and monitoring, site oversight, and verification of scientific and regulatory compliance. Beyond clinical operations, the company offers capabilities in regulatory affairs, medical writing, pharmacovigilance, and real-world data programs.

With an operational presence in multiple countries, the CRO manages multicenter projects across diverse regulatory environments and serves a portfolio of institutional and private clients. In 2025, revenue reached approximately €3 million, supported by the completion of more than 300 projects since inception. The company projects average growth of around 12% over the next three years, excluding potential group synergies, and expects an EBITDA margin of approximately 20% in 2025.

A structured transactional framework in line with the Oxurion model

• Oxurion plans to acquire 75% of the target company’s share capital.
• The transaction values the target company at €3,712,500 on a 100% basis.
• Financing will combine cash and Oxurion shares, with management aiming to maximize the use of non-dilutive instruments.
• Completion is subject to financial, legal, and technical due diligence, commencing in March and expected to conclude by the end of May 2026.
• Closing will also depend on agreement of definitive legal documentation and, where applicable, the fulfillment of legal requirements, including employee information and foreign direct investment procedures for French strategic assets.
• Oxurion has secured an exclusivity period until June 30, 2026, which may be extended. During this period, the target company and its sellers will not engage in discussions with third parties regarding any competing transaction.

A strategic operation to strengthen Oxurion’s integrated platform

Integrating this CRO would be a key milestone in Oxurion’s plan to build a cohesive, complementary group spanning the entire clinical development continuum. The fit is particularly strong with Axiodis’ data and biometrics expertise, enabling the combination of robust multicenter operational capabilities with advanced digital tools. Through this acquisition, Oxurion aims to reinforce its position in a growing market characterized by rising demand for partners capable of managing increasingly complex, end-to-end clinical programs.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) specializes in acquiring majority stakes in promising European pharmaceutical subcontractors. Its ambition is to build an integrated group of subcontractors serving healthcare stakeholders. The Group is headquartered in Leuven, Belgium.

Important information about forward-looking statements

Certain statements in this announcement may be considered forward-looking. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. No assurance can be given that such forward-looking statements will materialize. Oxurion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information on risks and uncertainties that could affect results is included in the Company’s Annual Report. This announcement does not constitute an offer or invitation to sell or purchase securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an applicable exemption, and in accordance with any relevant U.S. state securities laws.

Additional disclaimer

The planned investment in digital assets (such as Bitcoin and Ethereum) exposes the company to specific risks related to volatility, regulatory uncertainty, and cybersecurity. These factors may significantly affect the expected performance of such investments.